A Study in Pediatric Participants With Generalized Anxiety Disorder

Anxiety Neuroses Clinical Trial

Official title:
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Status Completed

Clinical Trial Summary

The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01226511
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	June 2011
Completion date	June 2013

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00150449` - Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.	Phase 3
	Completed	`NCT00534599` - Generalized Anxiety Disorder Adjunct Study	Phase 3